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Background: Genotyping assays often require substantial amounts of DNA. To overcome the problem of limiting
amounts of available DNA, Whole Genome Amplification (WGA) methods have been developed. The multiple
displacement amplification (MDA) method using Φ29 polymerase has become the preferred choice due to its high
processivity and low error rate. However, the uniformity and fidelity of the amplification process across the genome
has not been extensively characterized.
Results: To assess amplification uniformity, we used array-based comparative genomic hybridization (aCGH) to
evaluate DNA copy number variations (CNVs) in DNAs amplified by two MDA kits: GenomiPhi and REPLI-g. The
Agilent Human CGH array containing nearly one million probes was used in this study together with DNAs from a
normal subject and 2 cystic fibrosis (CF) patients. Each DNA sample was amplified 4 independent times and
compared to its native unamplified DNA. Komogorov distances and Phi correlations showed a high consistency
within each sample group. Less than 2% of the probes showed more than 2-fold CNV introduced by the
amplification process. The two amplification kits, REPLI-g and GenomiPhi, generate very similar amplified DNA
samples despite the differences between the unamplified and amplified DNA samples. The results from aCGH
analysis indicated that there were no obvious CNVs in the CFTR gene region due to WGA when compared to
unamplified DNA. This was confirmed by quantitative real-time PCR copy number assays at 10 locations within
the CFTR gene. DNA sequencing analysis of a 2-kb region within the CFTR gene showed no mutations introduced
by WGA.
Conclusion: The relatively high uniformity and consistency of the WGA process, coupled with the low replication
error rate, suggests that WGA DNA may be suitable for accurate genotyping. Regions of the genome that were
consistently under-amplified were found to contain higher than average GC content. Because of the consistent
differences between the WGA DNA and the native unamplified DNA, characterization of the genomic region of
interest, as described here, will be necessary to ensure the reliability of genotyping results from WGA DNA.
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Advances in genomic technologies have enabled devel-
opment of many novel genome analysis methods that
may have applications in the understanding, diagnosis,
and management of genetic diseases and cancer. Com-
prehensive high-throughput assays are available for de-
tection of single nucleotide polymorphisms (SNPs) [1-3],
DNA copy number variation (CNV) [4], microsatellite
expansion or contraction [5] and loss of heterozygosity
(LOH) [6], all of which detect sometimes subtle genomic
alterations associated with disease. Some of these assays
require micrograms of DNA which may be difficult to
obtain for many clinical samples. In addition, inadequate
DNA template may prevent the performance of multiple
assays on a single sample [7]. Limited availability of
DNA also poses challenges for manufacturers and reg-
ulators of genetic diagnostic devices. One of these
challenges is availability of sufficient quantities of DNA
samples to appropriately validate a particular test
under investigation, especially when uncommon muta-
tions for a rare disease severely limit access to patient
sample specimens.
Since the U.S. Food and Drug Administration
(FDA)’s clearance of the first genotyping assay for cys-
tic fibrosis (CF) in 2005, the Office of In Vitro Diag-
nostic Device Evaluation and Safety within the Center
for Devices and Radiological Health (CDRH) has
reviewed a number of other genotyping assays for
inherited disorders. Some of these genotyping assays
are intended to detect relatively rare heritable diseases
consisting of multiple disease-causing alleles (muta-
tions) for each disease, while others may detect more
common diseases, but are intended to test very rare as
well as common mutations. To show the accuracy of
these assays, manufacturers would generally use patient
samples (whole blood or archived DNA). For rare
mutations or alleles, it is often difficult to obtain suffi-
cient quantities of such clinical samples to adequately
assess test performance. Therefore, there is an interest in
using whole genome amplified (WGA) DNA samples
created from patient samples instead of native DNA sam-
ples to increase the availability of appropriate samples to
query the performance of the assays. WGA is a method
that amplifies small amounts of genomic DNA several
thousand-fold in vitro. The WGA process has the poten-
tial, however, to result in non-uniform amplification of
the DNA in which some regions of the genome are over-
represented and others are under-represented. Such
biased amplification could make the WGA DNA unsuit-
able for some of the studies designed to assess the clin-
ical assay performance.
Several WGA methods based on the polymerase chain
reaction (PCR) with Taq polymerase were initially devel-
oped [8-12]. These methods included the use of primersdirected at highly repetitive sequences [11], ligation of
linkers to fragmented DNA [12], degenerate oligo-
nucleotide primed PCR [9], and primer extension pre-
amplification [10]. All of these methods suffer from a
relatively high level of mutations in the amplified DNA
(error rate 3x10-5 [13]) and highly non-uniform amplifi-
cation due to the low fidelity and low processivity of the
Taq polymerase, respectively. In 2002, Dean et al. [14]
described the multiple displacement amplification
(MDA) technique. This method of WGA takes advan-
tage of the high processivity and low error rate of the
Φ29 bacteriophage DNA polymerase. This polymerase
has a 3’-5’ proof-reading activity and adds an average of
70,000 templated nucleotides to a primer [15], resulting
in higher fidelity and less biased amplification than with
the Taq polymerase methods. The WGA process using
Φ29 polymerase is isothermal and uses random primers
to target the entire genome. The polymerase has strong
strand displacement activity so that exponential amplifi-
cation occurs through a branching mechanism [14],
resulting in a high yield of DNA. The MDA process has
been recently reviewed and shown to be superior to
other DNA amplification methods with regard to geno-
typing, genomic coverage, and amplification bias [16,17].
MDA-based WGA has been frequently used in DNA
sample preparation for genotyping and sequencing in re-
cent years [18-21]. High call rates (97.5%) and excellent
concordance rates were achieved from WGA samples
using high-density SNP arrays [19,20]. There was a very
low error rate (1 SNP genotyping error per 1000 assays)
when high quality DNA was used as template [21].
MDA-based WGA has also been used for analyses of
single cells [22,23]. Jiang et al. successfully amplified
DNA from single sperm at least 250 fold with a single
round of MDA [24]. DNA amplified from single lym-
phocytes was used for multiple analyses of 20 different
loci including the ΔF508 deletion in exon 10 and two
intragenic microsatellite markers in the CF gene [25].
Short tandem repeats (STR) and Human Leucocyte
Antigen typing were performed using DNA amplified by
MDA from a single cell [26]. MDA-WGA has also been
increasingly used in the field of forensic testing [27,28].
Even in the often degraded DNA samples, WGA
showed the capability and potential to increase the
quality and quantity of DNA from difficult samples in
forensic casework [29]. Although MDA-based WGA
has been successfully applied in many studies, there are
several potential problems that may affect interpretation
of results. These include the finding that large amounts
of nonspecific DNA amplification can be generated dur-
ing MDA, mostly due to primer-directed DNA synthe-
sis [5,30], and the quantity [21,31] and quality [32] of
input DNA into the MDA reaction can affect genotyp-
ing results.
Table 1 DNA sample information
Sample Visit/Blood Ethnicity Sex Age Genotype Diagnosis OD260/280
Draw date
Normal 9/27/2002 Caucasian M 52 Control 1.76
CF1 10/30/2003 Caucasian M 26 2xF508 Cystic Fibrosis 1.84
CF2 10/30/2003 Caucasian F 20 1xG542X Cystic Fibrosis 1.83
1x3659delC
DNA samples were purchased from PrecisionMed, Inc. and dissolved in TE buffer (10 mM Tris, 1 mM EDTA at pH 8.0). There are different mutations in the two
patients with cystic fibrosis (CF1 and CF2).
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method, the uniformity of the amplification process
across the genome has not been extensively character-
ized [3,4,33]. In 2004, Paez et al. [33] examined DNAs
amplified using a commercially available MDA method,
REPLI-g, using 10 k Affymetrix SNP arrays and direct
sequencing of ~500,000 bp of DNA and showed near-
complete genome representation, as well as low replica-
tion error rate. In 2006, Pinard et al. [34] assessed the
bias of WGA methods on bacterial genomes using mas-
sively parallel sequencing and found statistically signifi-
cant amplification bias, although the MDA methods
produced the least bias. Arriola et al. (2007) [35], using a
second commercially available MDA method, Genomi-
Phi, evaluated the WGA DNA with low density array
comparative genomic hybridization (aCGH), a method
with higher resolution (~ 200 kb in this case) than the
traditional CGH method [36]. Copy number biases were
found, with the extent dependent on the degree of amp-
lification. While these studies and others [16,17] have
consistently shown non-uniformity of amplification by
the MDA methods (although less than with other WGA
methods), the uniformity of amplification has not been
examined with high resolution aCGH at a resolution of
several kb. In addition, the consistency of the amplifica-
tion process has not been evaluated in replicate amplifi-
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Figure 1 aCGH experimental design with 4 replications each for Geno
individual (Normal) and two patients with cystic fibrosis (CF1 and CF2).when such material may be used for validation of genetic
diagnostic devices or tests.
In this study, we evaluated two commonly used meth-
ods of WGA for their ability to produce large quantities
of uniformly amplified DNA with minimal introduced
mutations. Biases during the amplification process were
determined by measurements of DNA CNVs at nearly 1
million positions in the genome using aCGH analysis.
Particular attention was given to a single gene, CFTR,
which encodes cystic fibrosis transmembrane conduct-
ance regulator. Mutations in CFTR can cause cystic fi-
brosis, a rare disease manifested by thick, sticky mucus
and salty sweat, which usually leads to lung transplant or
early death [37]. In addition to aCGH, copy number vari-
ation in the CFTR gene was examined by a second
method, quantitative real-time PCR. Finally, the intro-
duction of mutations during the WGA process was
examined by comparing the DNA sequence of the result-
ing amplified DNA to that of the unamplified DNA. The
consistency of the WGA process was evaluated by exam-
ining four replicate amplified DNAs derived from three
individuals, one healthy and two with cystic fibrosis.
Results
CNV introduced by the WGA process
To characterize the consistency and faithfulness of






miPhi and REPLI-g. DNAs used in this study were from one healthy












Figure 2 Box plot of log2 ratios of samples to unamplified samples for Normal, CF1, and CF2 samples. The average of the 4 replicates in
each sample group is shown. UnAmp (no amplification); Amp-R (REPLI-g amplified); Amp-G (GenomiPhi amplified).
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http://www.biomedcentral.com/1471-2164/13/217polymerase, three human DNA samples (Table 1) were
amplified using two commercially available kits, REPLI-g
and GenomiPhi. The DNA samples were derived from a
healthy individual (Normal) and two patients with cystic
fibrosis (CF1 and CF2). The experimental design is
shown in Figure 1. Each of the three DNA samples was
amplified 4 independent times by both REPLI-g and
GenomiPhi kits. DNA copy number changes introduced
into the amplified DNA were evaluated by comparing
the amplified DNA to the native unamplified DNA util-
izing aCGH. The Agilent Human CGH array was usedTable 2 Pair-wise comparison of Kolmogorov distances betwe
Normal patient DNA samples
Sample
Replicate 1








Each row represents probe ratio distributions from replications of amplified DNA sa
unamplified DNA samples. The median values are 0.407 and 0.368 for REPLI-g and G
(REPLI-g amplified samples); Amp-G (GenomiPhi amplified samples).with the assumption that as a research tool it could
comprehensively evaluate and reveal gross copy number
changes at nearly 1 million loci. In addition, unamplified
Normal samples were compared to unamplified Normal
samples four times to define the technical variability of
the aCGH process. Any copy number variation in such a
self-self hybridization would be due to technical limits of
the aCGH process since the DNA samples were identi-
cal. A total of 28 CGH arrays were used in this study.
Figure 2 shows box plots of the average log2 ratios of
amplified or unamplified test samples versus theen probe ratio distributions of unamplified and amplified
Kolmogorov distance
Normal UnAmp/UnAmp









mples; each column represents probe ratio distributions from replications of
enomiPhi, respectively. UnAmp (unamplified samples); Amp-R











Normal UnAmp/UnAmp 0.004 0.000 0.000 0.000 0.000
Amp-R/UnAmp 2.043 0.525 0.194 0.077 0.010
Amp-G/UnAmp 8.139 1.273 0.339 0.109 0.017
CF1 Amp-R/UnAmp 2.191 0.478 0.162 0.057 0.010
Amp-G/UnAmp 3.682 0.747 0.230 0.074 0.015
CF2 Amp-R/UnAmp 1.913 0.486 0.192 0.075 0.007
Amp-G/UnAmp 2.883 0.605 0.183 0.061 0.015
* Indicates samples on the CGH array. The averages of the 4 replicate WGA are given. UnAmp (unamplified samples); Amp-R (REPLI-g amplified samples);
Amp-G (GenomiPhi amplified samples).
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http://www.biomedcentral.com/1471-2164/13/217corresponding native unamplified sample. The first plot
shows the distribution of average log2 ratios of unampli-
fied Normal DNA vs. unamplified Normal DNA (self-self
hybridization). The distribution is centered at 0 and is
very tight, indicating that little variability (i.e., CNV
“noise”) is introduced by the aCGH process itself. Sup-
porting this conclusion, the derivative log2 ratio spread
(which is the average log ratio difference between adja-
cent probes of an array) for the 4 replicate self-self
hybridizations was low (0.165). Thus, any change in the
distribution of log2 ratios in amplified samples comparedTable 4 Common highly under-amplified regions (>3 fold) in
Chromosome Cytoband Stat (bp)






Chr9 q34.2 - q34.3 136872507
Chr10 p15.3 499391













Cytobands and chromosomal locations are based on hg 19 (NCBI Genome build 37
* total number of genes located within the under-amplified regions.to unamplified samples could be considered to be due
primarily to the WGA process. A notably wider distribu-
tion of the ratios was observed for the amplified samples
compared to the unamplified samples although the me-
dian was still close to 0. These results suggest that CGH
arrays can be sensitive tools for this type of CNV ana-
lysis. More importantly, WGA resulted in CNV changes
for all three samples. The majority of the CNV changes
were due to under-amplification.
To better understand differences in copy number
introduced by the WGA process, we compared theNormal, CF1, and CF2 samples after WGA























Table 5 Pair-wise comparison of Kolmogorov distances between probe ratio distributions within each sample group
Sample* Kolmogorov distance
Replicate 1 Replicate 2 Replicate 3 Replicate 4
Normal Replicate 1 0 0.025
UnAmp/UnAmp Replicate 2 0.019 0
Replicate 3 0.026 0.044 0
Replicate 4 0.024 0.018 0.049 0
Normal Replicate 1 0 0.013
Amp-R/UnAmp Replicate 2 0.009 0
Replicate 3 0.011 0.005 0
Replicate 4 0.015 0.020 0.021 0
Normal Replicate 1 0 0.029
Amp-G/UnAmp Replicate 2 0.026 0
Replicate 3 0.020 0.033 0
Replicate 4 0.048 0.023 0.053 0
CF1 Replicate 1 0 0.085
Amp-R/UnAmp Replicate 2 0.108 0
Replicate 3 0.046 0.062 0
Replicate 4 0.065 0.062 0.120 0
CF1 Replicate 1 0 0.053
Amp-G/UnAmp Replicate 2 0.050 0
Replicate 3 0.056 0.023 0
Replicate 4 0.042 0.082 0.095 0
CF2 Replicate 1 0 0.047
Amp-R/UnAmp Replicate 2 0.003 0
Replicate 3 0.065 0.066 0
Replicate 4 0.029 0.029 0.088 0
CF2 Replicate 1 0 0.039
Amp-G/UnAmp Replicate 2 0.018 0
Replicate 3 0.050 0.036 0
Replicate 4 0.055 0.043 0.009 0
* Indicates samples on CGH array.
The median values for each group are shown in bold. UnAmp (unamplified samples); Amp-R (REPLI-g amplified samples); Amp-G (GenomiPhi amplified samples).
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DNA vs. Normal unamplified DNA (self-self ) with
the log2 ratio distribution of the WGA Normal
(amplified) DNA vs. Normal unamplified DNA by
calculating the Kolmogorov distances. The pair-wise
comparisons for both the REPLI-g and GenomiPhi
WGA methods are shown in Table 2. The median
pair-wise Kolmogorov distances between the REPLI-
g-amplified vs. unamplified distribution and Genomi-
Phi-amplified vs. unamplified distribution are 0.407
and 0.368, respectively, consistent with differences
between the distributions of log2 ratios before and
after WGA.
Another measure of the uniformity of the WGA
process is the percentage of probes with ratios below orabove a certain cut-off value when the WGA DNA is
compared to the unamplified DNA. Table 3 shows the
percentage of probes on the CGH arrays with ratios
greater than 1.5-fold, 2-fold, 2.5-fold, 3-fold, and 4-fold
for the three DNA samples and the two WGA methods.
The percentages are the average of the 4 replicates. Also
shown is the percentage of probes above these cut-offs
for the unamplified Normal DNA compared to itself; all
ratios were within 2, consistent with low variability of
the aCGH method. Both amplification methods resulted
in less than 1% of probes showing CNV of greater than
2-fold, with the exception of the Normal sample ampli-
fied by GenomiPhi (1.273%). If the fold-change criterion
was relaxed to 3-fold, less than approximately 0.1% of
probes showed CNV. Table 4 shows regions of the
Table 6 Pair-wise comparison of Phi correlations of probe ratios greater than 2 within each sample group after CBS
smoothing
Sample* Phi correlation value
Replicate 1 Replicate 2 Replicate 3 Replicate 4
Normal Replicate 1 1 1.000
UnAmp/UnAmp Replicate 2 1.000 1
Replicate 3 1.000 1.000 1
Replicate 4 1.000 1.000 1.000 1.000
Normal Replicate 1 1 0.842
Amp-R/UnAmp Replicate 2 0.855 1
Replicate 3 0.840 0.843 1
Replicate 4 0.877 0.840 0.809 1
Normal Replicate 1 1 0.805
Amp-G/UnAmp Replicate 2 0.853 1
Replicate 3 0.839 0.796 1
Replicate 4 0.773 0.814 0.707 1
CF1 Replicate 1 1 0.611
Amp-R/UnAmp Replicate 2 0.597 1
Replicate 3 0.764 0.665 1
Replicate 4 0.457 0.625 0.520 1
CF1
Amp-G/UnAmp
Replicate 1 1 0.667
Replicate 2 0.687 1
Replicate 3 0.679 0.777 1
Replicate 4 0.632 0.656 0.589 1
CF2 Replicate 1 1 0.768
Amp-R/UnAmp Replicate 2 0.824 1
Replicate 3 0.697 0.744 1
Replicate 4 0.796 0.793 0.707 1
CF2 Replicate 1 1 0.780
Amp-G/UnAmp Replicate 2 0.865 1
Replicate 3 0.798 0.746 1
Replicate 4 0.762 0.728 0.838 1
* Indicates samples on CGH array.
The median Phi correlation values from top to bottom are shown in bold. UnAmp (unamplified samples); Amp-R (REPLI-g amplified samples); Amp-G (GenomiPhi
amplified samples).
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http://www.biomedcentral.com/1471-2164/13/217genome that were consistently under-amplified by at
least 3-fold across all samples by both amplification
methods. These under-amplified regions represent a
small portion of total genome (2.1%), and contain about
1099 genes (approximately 4.4%). Thus, while the MDA
technology resulted in changes in copy number, the
changes were relatively small in most regions of the gen-
ome, and were concentrated in a relatively small number
of chromosomal loci.
Consistency of the WGA process
Differences in the distribution of ratios within each sam-
ple group were calculated using the Kolmogorovdistance. Table 5 shows pair-wise comparisons of Kol-
mogorov distances within each sample group, as well as
the median value for each group. The median Kolmo-
gorov value for the four self-self hybridizations (Normal
sample, unamplified vs. unamplified) was 0.025 and the
median Kolmogorov values within the other sample
groups were similarly low. Thus, the WGA process
appears to be reproducible in terms of uniformity of
amplification throughout the genome. The Phi correl-
ation was calculated to evaluate the consistency of the
position of the CNV loci (defined as having a ratio of
greater than 2). Higher values (greater than 0.7) indicate
the ratios at each probe location are very similar. Results




Replicate 1 Replicate 2 Replicate 3 Replicate 4
Normal Replicate 1 0.031 0.055 0.026 0.078
Amp-R/UnAmp Replicate 2 0.038 0.063 0.035 0.085
Replicate 3 0.041 0.065 0.037 0.088
Replicate 4 0.032 0.051 0.019 0.072
CF1 Replicate 1 0.095 0.050 0.041 0.131
Amp-R/UnAmp Replicate 2 0.017 0.061 0.071 0.025
Replicate 3 0.050 0.009 0.019 0.085
Replicate 4 0.079 0.115 0.130 0.037
CF2 Replicate 1 0.082 0.069 0.033 0.027
Amp-R/UnAmp Replicate 2 0.083 0.069 0.034 0.028
Replicate 3 0.021 0.019 0.034 0.039
Replicate 4 0.106 0.095 0.060 0.052
The median values for Normal, CF1, and CF2 groups between the WGA methods are 0.046, 0.055, and 0.046, respectively. Amp-R (REPLI-g amplified);
Amp-G (GenomiPhi amplified).
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http://www.biomedcentral.com/1471-2164/13/217of pair-wise Phi correlations (Table 6) indicate that the
majority of the replicates within each sample/amplifica-
tion group are highly correlated (similar patterns of
CNVs). The exception is the CF1 sample, which has a
Phi correlation just below 0.7. The Phi correlation values
are above 0.7 if the fold cut-off is set at 2.5 (data not
shown). Overall, the results from the Kolmogorov dis-
tances and Phi correlations show that there is high
consistency in the WGA process within each sample/




Normal Replicate 1 0.746
Amp-R/UnAmp Replicate 2 0.729
Replicate 3 0.688
Replicate 4 0.814
CF1 Replicate 1 0.736
Amp-R/UnAmp Replicate 2 0.842
Replicate 3 0.828
Replicate 4 0.733
CF2 Replicate 1 0.762
Amp-R/UnAmp Replicate 2 0.776
Replicate 3 0.789
Replicate 4 0.736
The median values for Normal, CF1, and CF2 groups were 0.738, 0.789, and 0.792, rComparisons between the two whole genome
amplification kits
Both WGA kits used in this study, REPLI-g and Geno-
miPhi, use the same bacterial phage Φ29 DNA polymer-
ase. However, the assay procedures are considerably
different with regard to reaction time (4 hr with Geno-
miPhi and 10 hr with REPLI-g) and method of DNA de-
naturation (heat with GenomiPhi and alkaline with
REPLI-g). Thus, comparison of outcomes of these proce-
dures is important. The median values of pair-wisetios greater than 2 between GenomiPhi and REPLI-g
Phi correlation value
Amp-G/UnAmp















Normal               CF1               CF2 Normal               CF1               CF2
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CFTR
Figure 3 Patterns of CNVs on chromosome 7 with amplified samples after smoothing (CBS). The average of the 4 replicates in each
sample group is shown and compared with the unamplified sample DNA. The CFTR gene is located at cytoband 7q31.2 on chromosome 7.
The numbers along the top of the graphs indicate log 2 ratios of probes.
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http://www.biomedcentral.com/1471-2164/13/217Kolmogorov distances for Normal, CF1, and CF2 sam-
ples between REPLI-g and GenomiPhi amplified samples
are 0.046, 0.055, and 0.046, respectively (Table 7) which
are similar to the Kolmogorov distances from samples
amplified by the same method (range: 0.013- 0.085; see
Table 4). The median pair-wise Phi correlations for Nor-
mal, CF1, and CF2 samples between REPLI-g and Geno-
miPhi amplified samples after CBS smoothing are 0.739,
0.789 and 0.792, respectively (Table 8). Again, theseTable 9 Probe information for TaqMan Copy Number Quantit











Chromosome locations are based on NCBI Human Genome Build 37.values are similar to those obtained when comparing
within an amplification method (see Table 6). These
results indicate that the two amplification methods gen-
erate similar amplified DNA samples despite the proced-
ural differences.
Visual comparison of CNV generated by these amplifi-
cation methods across chromosome 7 is illustrated in
Figure 3. The pattern of CNVs is similar between the 2
amplification methods and among the 3 DNAative PCR
CFTR location Chromosome location (Approx.)
Intron 1 Chr7: 117122192
Intron 2 Chr7: 117145581
Intron 3 Chr7: 117153814
Intron 9 Chr7: 117185643
Intron 11 Chr7: 117203673
Intron 12 Chr7: 117228242
Intron 15 Chr7: 117238610
Intron 18 Chr7: 117247359
Intron 23 Chr7: 117282984
Intron 27 Chr7: 117307221
Figure 4 A schematic diagram of the PCR probe locations and a 2-kb sequencing region of the CFTR gene on chromosome 7. The blue
boxes show the locations of the PCR probes (see Table 8). The small red box highlights the 2 kb region of the CFTR gene that was sequenced.
This DNA segment includes part of intron 11 and exon 12, which account for 1% of the gene.
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http://www.biomedcentral.com/1471-2164/13/217specimens, with much of the chromosome showing
CNV< 2-fold when compared to the unamplified DNA.
However, regions with consistent >2-fold CNV are evi-
dent near the chromosomal ends, as well as near 7q21.3,
7q11.22, and 7p14.1, among others. The region near the
CFTR gene appears to amplify uniformly and contains
no CNVs greater than 2-fold.
Quantitative real-time PCR copy number assay within the
CFTR gene region
Subsequent to array analysis, a quantitative PCR method
was used to further evaluate the variability between the
amplified and unamplified DNA samples. Ten TaqMan
Copy Number PCR probes were selected from Applied
Biosystem’s pre-designed research assays across the
length of the CFTR gene, a well-studied genetic disease
locus, representing 9 introns and 1 exon (Table 9 and
Figure 4). Relative copy number was calculated for each
probe in reference to the unamplified DNA sample for
each subject. Each of the ten probes gave comparable
results showing less than 2-fold difference (considering
both over- and under-amplification) in fold-change be-
tween amplified and unamplified DNA samples (Figure 5).
This low level of variability was also evident when com-
































Figure 5 Quantitative real time PCR copy number assays. Taqman assa
within the CFTR gene in both the unamplified and amplified DNA samples
representing minimum and maximum values from replicate measurements
probe results is I- X (see Figure 4). UnAmp (no amplification); Amp-R (REPL(REPLI-g and GenomiPhi), suggesting comparable results
irrespective of the manufacturer’s protocol. Furthermore,
the amount of variability across the three human sam-
ples was similar, suggesting robust amplification results
regardless of possible biological differences. Thus, the
TaqMan Copy Number PCR results are in agreement
with the aCGH data (Figure 3) in identifying low levels
(below 2-fold change) of amplification variability intro-
duced by the WGA process in the CFTR locus.
DNA sequence analysis in the CFTR gene region
Bidirectional Sanger DNA sequencing was performed
on an approximately 2 kb region of the CFTR gene to
examine the fidelity of the WGA process using primers
shown in Table 10 (see Methods). DNA sequences
from the WGA samples were compared with the re-
spective unamplified DNA samples. The results are
shown in Table 11 and there were no detectable muta-
tions introduced by either WGA method in the 3 DNA
samples (approximate 7,900 nucleotides examined for
each sample/WGA method). Thus, the level of detect-
able mutations introduced by the GenomiPhi and
REPLI-g WGA methods in this analysis was less than
1 mutation per 23,000 nucleotides examined. These
results suggest that both GenomiPhi and REPLI-gumber Assays
CF2CF1
pmAnU R-pmAmp-R G-pmAAmp-G
ys were used to examine copy number variations at 10 locations
. Average calculated copy number values are plotted with bars
(n = 4). Within each amplification / sample group, the order of the
I-g amplified); Amp-G (GenomiPhi amplified).
Table 10 Sequencing primer information
Primer Name Primer location Primer sequence (5’- 3’) Tm Amplicon size (bp)
Seq1_F 112776-112797 GGACATCTCCAAGTTTGCAGAG 66 760
Seq1_R 113535-113512 GAAACATTTGACATCAGAGTCAC 64
Seq2_F 113459-113479 GTCAAGGAGAGAGCTTTGTGG 64 729
Seq2_R 114187-114165 TGGACAACACATTACACATTCTG 64
Seq3_F 114050-114071 GGCTTCTAGACATCCAACATAG 64 756
Seq3_R 114805-114784 GATAGCAGTGCTGCCACAACTG 68
Primer locations (chromsome 7) are based on NCBI reference sequence NG_016465.1. “F” –forward primer; “R”- Reverse primer.
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ing nanogram quantities of starting DNAs to micro-
gram levels.
Discussion
The sequencing of the human genome, coupled with
advances in genomics technologies, is having a major
impact on understanding basic human biology, as well
as the molecular causes of diseases and toxicities [38]. In
fact, the leaders of the U.S. Food and Drug Administra-
tion (FDA) and the National Institutes of Health (NIH)
have recently outlined the opportunities in clinical medi-
cine that are being created by advances in basic science,
including genomics [39]. The two agencies have
announced a new collaborative effort to focus regulatory
and translational sciences on bringing medical products
and therapies into the age of personalized medicine. This
growing store of knowledge has enormous potential ap-
plication to the development of devices and tests for use
in the diagnosis, mitigation, treatment, cure, and preven-
tion of disease and other conditions.
As of 2010, more than 100,000 germline mutations in
more than 3700 genes have been associated with human
inherited disease, with about 300 new disease genes and
10,000 mutations being identified annually [40]. In
principle, DNA tests could be developed for each of
these conditions. Development and approval of such
tests for clinical diagnostics often require that accuracy
be demonstrated on patient samples. That is, the test
needs to detect the disease-causing mutation with high
precision and accuracy. In addition, measures ofTable 11 Mutations in the WGA DNA







Nucleotides examined are the sum of 2-kb sequences from the four replications.proficiency are required by testing laboratories to ensure
continued accuracy of the results. The Clinical Labora-
tory Improvement Advisory Committee has recently
issued a good practices report for molecular genetic test-
ing and has stressed the need for performance assess-
ments [41]. Such recommendations are supportive of the
2008 Report of the Secretary’s Advisory Committee on
Genetics, Health, and Society (SACGHS) [42]. Addition-
ally, the SACGHS has identified the development of gen-
etic reference materials as one of five critical gaps in the
oversight system of genetic testing [42]. The device ap-
proval process, use of reference and control materials,
and ongoing proficiency assessments require relatively
large quantities of clinical samples in order to assure
test performance is adequate and maintained over
time. The availability of sufficient samples with appro-
priate mutations has been recognized as a critical issue
in genetic testing, given the paucity of validated clin-
ical inherited disease gene samples [43]. Therefore,
methods that can expand the limited supply of vali-
dated clinical samples would have major impacts on
both the test and device performance evaluation and
approval process, and the on-going proficiency assess-
ment of the test providers.
The importance of the amount of template DNA for
MDA-based WGA has been thoroughly discussed for
SNP assays and STR genotyping in previous studies
[28,31]. For example, large number of SNPs could be ac-
curately detected from as low as 0.01 ng of DNA tem-
plate [27,28] and even degraded DNA samples can be
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typing [31]. In this study, we mainly focused on evalu-
ating the uniformity and fidelity of WGA DNAs using
CGH arrays, TaqMan copy number assays, and DNA
sequencing. The results indicated the amplified DNA
and its native unamplified DNA that we examined
were similar, although not identical, in terms of DNA
copy number variation. Importantly, no detectable
introduced mutations were found under our experi-
mental conditions.
The Agilent Human CGH array used in this study
includes approximately 970,000 probes at 1 to 2 kb
intervals throughout the human genome. To ensure the
quality of this study, four independent replications for
both the WGA and aCGH processes were used. The
self-self hybridization of unamplified Normal DNA sam-
ples provided us the base-line measurement of noise for
aCGH technology. The box plot of unamplified Normal
samples indicated less than 0.004% of the approximately
970,000 probes on the CGH array have fold changes
greater than 1.5 and no CNVs can be detected by aCGH
(Figure 2 and Table 3). The low Kolmogorov distances
(0.025) and high Phi correlations (1.00) between the four
replicates of unamplified samples further showed the
aCGH technology was reproducible and could be a reli-
able tool to access variability of the WGA process.
The WGA technologies have evolved over the years
from Taq DNA polymerase-based (PCR-based) to bac-
teriophage Ф29 DNA polymerase-based methods
(MDA). We focused on MDA methods in this study be-
cause of the processivity and reportedly low replication
error rate of the Ф29 DNA polymerase. In this study, we
compared two MDA-based commercial WGA kits: the
REPLI-g and GenomiPhi kits. The comparison between
the unamplified and amplified DNA samples showed
that relatively few probes (approximately 1% or less)
were over- or under-amplified by more than 2-fold
(Table 3). GenomiPhi-amplified DNA, however, showed
consistently more CNVs than the REPLI-g-amplified
DNA. Kolmogorov distances also indicated that differ-
ences in the distribution of DNA copy number existed
between the unamplified and amplified samples (Table 2),
and that these differences were greater than the differ-
ences between the REPLI-g and GenomiPhi amplified
samples (Table 7). Thus, even though the kits differ in
method of DNA denaturation (heat vs. alkaline), buffer
composition, and reaction time (4 hr vs. 10 hr), they
produce similar amplified DNA, likely the result of the
common Ф29 DNA polymerase.
The data in this report indicate that the two WGA meth-
ods examined can consistently amplify small amounts of
DNA (ng) to large quantities (~40 μg) with relatively small
changes in DNA copy number along the chromosomes.
Changes in DNA copy number of greater than 3-fold areevident as under-amplified regions at the ends of chromo-
somes, as illustrated in Figure 3, and in discrete regions on
many of the chromosomes (Table 4). Because of the
consistency of the DNA amplification, knowledge of the
positions of likely under-amplification can prevent the in-
appropriate use of WGA DNA. Results presented in Table 4
may serve as a reference guide to avoid target genes in
these regions. Inspection of the GC content within these
consistently under-amplified regions showed an average
GC content of nearly 53% which was higher than the over-
all GC content of the human genome of 41%. Further
investigations will be needed to evaluate the significance of
this observation.
Cystic fibrosis (CF) is caused by severe dysfunction of
cystic fibrosis transmembrane conductance regulator
(CFTR), which commonly leads to progressive lung dis-
ease and a shortened life [44]. Currently, there is no cure
available for CF, even though multiple interventions have
been developed to slow its progression. Since the FDA
cleared the first genotyping assay for CF in 2005, manu-
facturers have developed a number of genotyping tests for
rare heritable diseases caused by multiple mutant alleles,
using patient samples to assess performance. There is an
increased interest in using WGA DNA samples created
from patient samples to support the performance of the
assays. This study shows that within certain limits, the
WGA process produces large quantities of DNA that may
be useful for this purpose. To address the concerns of
mutations introduced by WGA, TaqMan copy number
assays were used to analyze CNVs at 10 locations within
CFTR gene region and a random selected 2 kb region in
CFTR gene was also sequenced. Results from the TaqMan
copy number assay are in excellent agreement with the
aCGH results. The DNA sequencing analysis showed
there were no mutations induced by WGA in this ap-
proximately 2 kb region of the CFTR gene (mutation in-
duction was less than 4 x 10-5), which indicates that WGA
DNAs can be used for enrichment of DNA samples for
cystic fibrosis genotyping assays.
The objective of the study presented here was to deter-
mine whether WGA amplified samples may be a reliable
alternative to native clinical specimens for assessing the
performance of a test under investigation. The conclu-
sions from this study provide scientific input that may
serve to support regulatory decisions in the ascertain-
ment of safety and effectiveness of diagnostic products
that use whole genome amplified samples in clinical
studies. This study may serve as a guide to the technical
qualification of WGA DNA for assessing the perform-
ance of genotyping assays.
Conclusions
In summary, WGA generates large quantities of DNA
with relatively high uniformity and low replication error
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that WGA DNA may be suitable for accurate genotyp-
ing. However, because there are consistent differences
between the WGA DNA and the native unamplified
DNA, characterization of the genomic region of interest,
as described here, will be necessary to ensure the reli-
ability of genotyping results from WGA DNA.
Methods
DNA Samples: DNA samples used in this study were pur-
chased from PrecisionMed, Inc. (San Diego, CA) and are
shown in Table 1. All three DNA samples were extracted
from human blood and were dissolved in TE buffer
(1 mM EDTA, 10 mM Tris at pH 8.0). The concentration
and purity (A260/280 ratio) of chromosomal DNA was
measured by the NanoDrop 1000 and PicoGreen methods
(Life Technologies, Carlsbad, CA). DNA samples were ali-
quoted to four batches and stored at −20 °C before use.
Whole Genome Amplification (WGA): Two WGA
kits, GenomiPhi (GE Healthcare, Piscataway, NJ ) and
REPLI-g (Qiagen, Inc., Hilden, Germany), were used in
this study. 20 ng of DNA template was used for the
amplification process using the manufacturers' recom-
mended protocols (Illustra GenomiPhi HY DNA Ampli-
fication kit protocol and REPLI-g Mini/Midi Handbook).
The GenomiPhi reaction was allowed to proceed for
4 hr while the REPLI-g reaction was allowed to proceed
for 10 hr. Both kits use the same phage Φ29 DNA poly-
merase to amplify the DNA templates, although the buf-
fer components are proprietary. The average yields after
WGA with GenomiPhi and REPLI-g were 37.5 μg and
14.0 μg DNA, respectively.
Array Comparative Genome Hybridization (aCGH):
The Agilent (Santa Clara, CA) 1 M human CGH array
used in this study is based on NCBI Build 37 (UCSC)
with 963,029 biological features and 6,685 controls. The
majority of the probes on this array have 1 to 2 kb spa-
cing along the human chromosomes. DNA labeling and
hybridization were performed following the Agilent
Oligonucleotide Array-Based CGH for Genomic DNA
Analysis protocol (V 6.1, 2009). One μg of genomic
DNAs were labeled with fluorescent dyes (Cy3 or Cy5-
dUTP). In this study, the amplified DNA samples were
labeled with Cy3 and unamplified DNA samples were la-
beled with Cy5. Labeled DNAs with specific activity
greater than 20 pmol of dye/μg DNA were used for
aCGH. Labeled amplified (Cy3) and unamplified (Cy5)
DNA samples were paired and co-hybridized to the
arrays at 65 °C for 40 hrs, then washed at room
temperature following the Agilent Oligonucleotide
Array-Based CGH for Genomic DNA Analysis protocol
(V 6.1, 2009). The hybridized array was immediately
scanned with an Agilent DNA Microarray Scanner (Agi-
lent Technologies, Inc.) at 2 μm resolution. Theresulting images were analyzed by quantifying the Cy3
and Cy5 fluorescence intensity at each feature on the
array using the Agilent Feature Extraction Software
(V10.5). The fluorescence intensity of each pixel within
the feature was determined and the median fluorescence
of these pixel measurements was taken as the measure
of fluorescence for the whole feature after subtraction of
background. Dye bias was removed by linear
normalization using the Agilent Feature Extraction Soft-
ware before the intensity values were used to calculate
ratios at each feature.
aCGH Data Analysis: Copy number variation (CNV)
was calculated at each locus along each chromosome as
the ratio of the sample (either unamplified or amplified)
to the unamplified sample intensities. A modified algo-
rithm [45] of the circular binary segmentation smooth-
ing method (CBS, [46]) was used to partition these ratio
measurements into chromosomal regions containing loci
with equal copy numbers. Regions with ratios less than 2
were then defined as being unchanged (no CNV). Two
approaches were used to measure the similarity of CNV
patterns. To measure the difference between the distri-
butions of ratios from different experimental groups,
Kolmogorov distances were calculated which are the
sub-distances between the distribution functions [47].
Low values indicate little difference between distribu-
tions. Phi correlation, which is a measure of association
for two binary variables [48], was calculated to meas-
ure the consistency of locations of the CNVs. A low
Kolmogorov distance coupled with a high Phi correl-
ation indicates highly uniform amplification. Agilent
Genomic Workbench 6.0 software (Agilent Technolo-
gies, Inc.) was also used to analyze CNVs along the
chromosomes utilizing the CBS module. Raw data were
imported into Agilent Genomic Workbench 6.0 for
CNV analysis. The four replicates for each sample were
combined based on the weight of each sample which is
proportional to its quality in Agilent Genomic Work-
bench before analysis. Average aberration reports (min-
imal 3 consecutive probes within each section) for
Normal, CF1, and CF2 after WGA were generated using
the CBS method with a fold change cut-off at 3-fold.
Cytobands with aberrations greater than 3 fold across
the six amplified samples are summarized in Table 4.
Quantitative Real Time PCR Copy Number Assays: Un-
amplified and amplified genomic DNAs (10 ng) were used
as templates in TaqMan Copy Number Assays (Applied
Biosystems, Carlsbad, CA) according to the manufacturer’s
protocol. Ten probes, distributed across the length of the
CFTR gene as illustrated in Figure 4, were used to quantify
copy number in each DNA sample using RNase P as the
reference assay. The Applied Biosystems probe IDs and
locations in the CFTR gene can be found in Table 9. Cycle
threshold (Ct) values were exported into Applied
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ber at each locus. Copy number values were standardized
to that of the unamplified DNA sample, according to soft-
ware recommendation. Average relative copy number
values were plotted along with minimum and maximum
values of replicate measurements (n=4).
DNA Sequencing Analysis: Unamplified and WGA
DNAs were sent to SeqWright, Inc. (Houston, TX) for de-
termination of the DNA sequence of a 2 kb region within
the CFTR gene. The 2 kb region was PCR- amplified as 3
overlapping segments of 760 bp, 729 bp, and 756 bp as
shown in Table 10 and Figure 4. The DNAs for sequen-
cing included the 4 replicate WGA samples for each
WGA method/DNA sample group (24 samples) plus one
sample of each of the unamplified DNA samples. The
DNA sequence of these amplicons was determined by bi-
directional fluorescent dye-terminator chemistry using an
ABI Prism 3730xl DNA sequencer. The sequencing data
were aligned using Sequencher software (Gene Code Cor-
poration, Ann Arbor, MI), which is based on an optimized
Smith-Waterman algorithm. Nucleotide positions in
which no base call was made or in which the forward base
call was different from the reverse base call were excluded
from further analysis. Of 23,744 bases examined after each
amplification method, 53 bases (0.2%) and 11 bases
(0.05%) were excluded after amplification with GenomiPhi
and REPLI-g, respectively.
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